CYTOKINETICS INC (CYTK:NASDAQ)
$78.33 3.12 (4.1484%)
Analysed CYTOKINETICS INC (CYTK:NASDAQ) News Sources
A Look At Cytokinetics (CYTK) Valuation After A Strong Multi‑Year Share Price Performance
25-05-2026
yahoo.com
Cytokinetics to Participate in June Investor Conferences
27-05-2026
yahoo.com
Citi Calls Cytokinetics, Incorporated (CYTK) a “Top Pick” Among Small-to-Mid Cap Biotech Stocks
28-05-2026
yahoo.com
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
01-06-2026
yahoo.com
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?
04-06-2026
yahoo.com
First MYQORZO Launch In Germany Might Change The Case For Investing In Cytokinetics (CYTK)
08-06-2026
yahoo.com
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
08-06-2026
yahoo.com
Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment
13-06-2026
yahoo.com
Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?
16-06-2026
yahoo.com
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?
17-06-2026
yahoo.com
What is the current price of CYTOKINETICS INC (CYTK:NASDAQ)?
The current price of CYTOKINETICS INC (CYTK:NASDAQ) is $78.33.
CYTOKINETICS INC (CYTK:NASDAQ) absolute price change since previous trading day?
The absolute price change of CYTOKINETICS INC (CYTK:NASDAQ) since the previous trading day is $3.12.
CYTOKINETICS INC (CYTK:NASDAQ) percentage price change since previous trading day?
The percentage price change of CYTOKINETICS INC (CYTK:NASDAQ) since the previous trading day is 4.1484%.
What is the most recent average sentiment score for CYTOKINETICS INC (CYTK:NASDAQ)?
The most recent average sentiment score for CYTOKINETICS INC (CYTK:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for CYTOKINETICS INC (CYTK:NASDAQ)?
The most recent sentiment for CYTOKINETICS INC (CYTK:NASDAQ) is .
SEC-8K** Filing Available For CYTOKINETICS INC (CYTK:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.